Ligand Pharmaceuticals LGND reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:01 PM.
Here's what investors need to know about the announcement.
Earnings
Ligand Pharmaceuticals their estimated earnings by 51.92%, reporting an EPS of $1.58 versus an estimate of $1.04, which surprised analysts.
Revenue was up $22,987,000 from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.29, which was followed by a 4.58% drop in the share price the next day.
Here's a look at Ligand Pharmaceuticals's past performance:
Quarter | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 |
---|---|---|---|---|
EPS Estimate | 1.34 | 1.12 | 0.99 | 0.98 |
EPS Actual | 1.63 | 1.41 | 1.62 | 1.04 |
Revenue Estimate | 70.41M | 62.85M | 54.09M | 44.36M |
Revenue Actual | 84.67M | 55.15M | 69.99M | 41.85M |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.